I contend it's medical providers who profit most from federal payment support.    I'm concerned that a federal/state agency would not would not be a fair arbitrator of price.   My fear is that big pharm and others, using their political influence, will 'negotiate' with Congress for prices that are unjustifiably high.   If those decision move to state level, large wealthy special interest have even more influence. What's being on a 'preferred' drug list worth to a pharmacuetical company?

This may be a strength for Pres. Trump.   If he uses his skill in the art of the deal, to save money for taxpayers, the I'd be the first to offer a toast.   Or, will he make a deal that favors the large shareholders of private industry who expects to profit from broader coverage and the US treasury promise to pay the bill? 
  
https://www.publicintegrity.org/2013/02/11/12175/opinion-big-pharmas-stranglehold-washington 

(I'd welcome other links to the same topic)